- Stocks
- Pharma & Healthcare
- Concord Biotech
Concord Biotech share price
NSE: CONCORDBIOPharma & HealthcareBiotechnology
Concord Biotech at a glance
Concord Biotech (NSE: CONCORDBIO) closed at ₹1,298.00 on 22 Oct 2026, up 1.80% on the day. With a market capitalisation of ₹13,286 Cr, it ranks 476th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
At its last close the stock traded at 52.4× trailing earnings. Over the past year the share price has fallen 14.6%. Its 52-week range is ₹987.00 (2 Apr 2026) to ₹1,615.00 (20 Aug 2026); the last close is 19.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹257 Cr (+26.2% year on year) and net profit ₹56 Cr (+32.5%), on a consolidated basis. Promoters held 44.08% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹13,286 CrRank 476 on NSE
- P/E (trailing)
- 52.4×
- Price to book
- 6.59×FY26
- EPS (TTM)
- ₹26.09to Q1 FY27
- Debt to equity
- 0FY26
- Net profit margin
- 24.8%FY26
- Book value / share
- ₹192.62FY26
- 52-week high
- ₹1,615.0020 Aug 2026
- 52-week low
- ₹987.002 Apr 2026
- 1-year return
- −14.6%
- RSI (14-day)
- 37.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +1.80% | −6.2% | −17.3% | +1.8% | −14.6% |
Concord Biotech quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹310 Cr | ₹244 Cr | ₹430 Cr | ₹204 Cr | ₹247 Cr | ₹278 Cr | ₹326 Cr | ₹257 Cr |
| Revenue YoY | +18.2% | +1.4% | +34.8% | −5.5% | −20.3% | +13.7% | −24.1% | +26.2% |
| Net profit | ₹99 Cr | ₹74 Cr | ₹142 Cr | ₹43 Cr | ₹61 Cr | ₹64 Cr | ₹89 Cr | ₹56 Cr |
| Net profit YoY | +16.8% | −0.6% | +46.0% | −26.9% | −38.4% | −13.2% | −37.6% | +32.5% |
| Net margin | 31.8% | 30.3% | 33.0% | 20.9% | 24.6% | 23.2% | 27.2% | 21.9% |
| EPS | ₹9.15 | ₹7.26 | ₹13.42 | ₹4.21 | ₹6.03 | ₹6.08 | ₹8.46 | ₹5.52 |
Concord Biotech financials
| Item | FY24 | FY25 |
|---|---|---|
| Revenue | ₹1,017 Cr | ₹1,200 Cr |
| Operating profit | ₹409 Cr | ₹496 Cr |
| Net profit | ₹305 Cr | ₹373 Cr |
| EPS (₹) | ₹29.00 | ₹36.00 |
| Cash from operations | ₹265 Cr | ₹245 Cr |
| Total debt | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹1,527 Cr | ₹1,813 Cr |
Concord Biotech shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% |
| Foreign institutions | 9.35% | 9.11% | 8.03% | 7.58% | 7.80% | 7.52% |
| Domestic institutions | 9.16% | 8.87% | 9.55% | 9.58% | 9.22% | 9.36% |
| Non-institutions | 37.41% | 37.95% | 38.33% | 38.76% | 38.90% | 39.03% |
Concord Biotech vs peers
The listed Pharma & Healthcare companies nearest to Concord Biotech by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| VIJAYAVijaya Diagnostic Centre | ₹1,382.60 | +2.04% | +42.1% | ₹14,324 Cr | 82.5 | 18.1% |
| NATCOPHARMNatco Pharma | ₹785.00 | +0.13% | −3.3% | ₹14,063 Cr | 9.9 | 15.4% |
| INDGNIndegene | ₹577.95 | −1.15% | +8.6% | ₹13,987 Cr | 34.8 | 12.8% |
| MARKSANSMarksans Pharma | ₹295.80 | −0.89% | +62.6% | ₹13,343 Cr | 32.1 | 13.8% |
| CONCORDBIOConcord Biotech | ₹1,298.00 | +1.80% | −14.6% | ₹13,286 Cr | 52.4 | — |
| CORONACORONA Remedies | ₹2,024.70 | −0.26% | — | ₹12,360 Cr | 66.8 | 24.8% |
| RAINBOWRainbow Childrens Medicare | ₹1,205.70 | −0.27% | −9.4% | ₹12,245 Cr | 43.9 | — |
Ask anything about Concord Biotech
Pivot answers on the live chart with evidence you can check, and tests strategies against CONCORDBIO's own history. Try: “Why has CONCORDBIO moved over the last three months?” · “Backtest a 50-day moving-average crossover on CONCORDBIO over five years” · “Compare CONCORDBIO with VIJAYA on margins and valuation”
Frequently asked questions about Concord Biotech
What is the share price of Concord Biotech today?
Concord Biotech (NSE: CONCORDBIO) last closed at ₹1,298.00 on 22 Oct 2026. Its 52-week high is ₹1,615.00 and its 52-week low is ₹987.00.
What is the market cap of Concord Biotech?
Concord Biotech's market capitalisation is ₹13,286 Cr (₹13,286 Cr) at the 22 Oct 2026 close, ranking 476th among the NSE companies Pivot tracks.
What is the P/E ratio of Concord Biotech?
Concord Biotech trades at a trailing P/E of 52.4. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 43.9.
Is Concord Biotech a debt-free company?
Concord Biotech is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Concord Biotech's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Concord Biotech reported revenue of ₹257 Cr, +26.2% year on year, and net profit of ₹56 Cr, +32.5% year on year.
How has Concord Biotech stock performed over the last year?
Concord Biotech's share price has fallen 14.6% over the past year, +1.8% over three months and −17.3% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Concord Biotech?
As of 30 Jun 2026: promoters 44.08%, foreign institutions 7.52%, domestic institutions 9.36%, non-institutions 39.03%.
Who are Concord Biotech's competitors?
The listed Pharma & Healthcare companies closest to Concord Biotech by market cap are Vijaya Diagnostic Centre, Natco Pharma, Indegene, Marksans Pharma, CORONA Remedies and Rainbow Childrens Medicare.
Is Concord Biotech a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Concord Biotech's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CONCORDBIO against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with C · all NSE stocks · this page as text